» Articles » PMID: 29417360

42,573 Cases of Hepatectomy in China: a Multicenter Retrospective Investigation

Abstract

Hepatectomy is currently routinely performed in most hospitals in China. China owns the largest population of liver diseases and the biggest number of liver resection cases. A nationwide multicenter retrospective investigation involving 112 hospitals was performed, and focused on liver resection for patients with hepatocellular carcinoma (HCC). 42,573 cases of hepatectomy were enrolled, and 18,275 valid cases of liver resection for HCC patients were selected for statistical analysis. The epidemiology of HCC, distribution of hepatectomy, postoperative complications and prognosis were finally analyzed. In the 18,275 HCC patients, 81% had hepatitis B virus infection and 10% had hepatitis C virus infection. 38% of the HCC patients had normal Alphafetoprotein (AFP) level, and other 35% had an AFP level lower than 400 ng mL. In the study period, 97% of the hepatectomy for HCC were treated with open surgery, and 23.81% had vascular exclusion techniques. The operation time was (191.7±105.6) min, the blood loss was (546.0±562.8) mL, and blood transfusion was (543.0±1,035.2) mL. The median survival for HCC patients was 631 days, with 1-, 3-, and 5-year overall survival of 73.2%, 28.8% and 19.6%, respectively. Liver cirrhosis, multiple nodules, tumor thrombosis and high AFP level were risk factors that affect postoperative survival.

Citing Articles

Association of intratumoral microbiome diversity with hepatocellular carcinoma prognosis.

Jiang F, Dang Y, Zhang Z, Yan Y, Wang Y, Chen Y mSystems. 2024; 10(1):e0076524.

PMID: 39660866 PMC: 11748501. DOI: 10.1128/msystems.00765-24.


Comparison of the outcomes between ultrasonic devices and clamping in hepatectomy: a meta-analysis.

Yu Z, Xu L, Li L, Zhang H, Ma Y, Wang L World J Surg Oncol. 2024; 22(1):304.

PMID: 39548479 PMC: 11568570. DOI: 10.1186/s12957-024-03575-3.


Serum CHI3L1 Levels Predict Overall Survival of Hepatocellular Carcinoma Patients after Hepatectomy.

Jiang Y, Gong W, Liu Y, Zhou Z, Liang X, Lin Q J Cancer. 2024; 15(19):6315-6325.

PMID: 39513118 PMC: 11540517. DOI: 10.7150/jca.100791.


The effect of CXCL12 on survival outcomes of patients with viral hepatitis-associated hepatocellular carcinoma after hepatectomy.

Lu Y, Xing F, Peng S Heliyon. 2024; 10(9):e30782.

PMID: 38756575 PMC: 11096947. DOI: 10.1016/j.heliyon.2024.e30782.


Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.

Lin K, Xia B, Wang X, He X, Zhou M, Lin Y J Transl Med. 2024; 22(1):349.

PMID: 38610029 PMC: 11015683. DOI: 10.1186/s12967-024-05159-x.